Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Income from Continuing Operations
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
|
Income from Continuing Operations
¥169m
|
CAGR 3-Years
16%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Income from Continuing Operations
¥19.3B
|
CAGR 3-Years
29%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Income from Continuing Operations
¥1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Income from Continuing Operations
¥5.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Income from Continuing Operations
¥805.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
17%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Income from Continuing Operations
¥1.5B
|
CAGR 3-Years
112%
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
|
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Glance View
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. engages in the research and development of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 873 full-time employees. The company went IPO on 2021-06-21. The firm's main businesses include comprehensive research and development services in generic drug development, consistency evaluation and innovative drug development. Its services mainly include pharmaceutical research, clinical trials and biological analysis. Pharmaceutical research services include raw materials and preparation process research, quality standards and stability research, etc. Clinical trial services include phase I-IV clinical trial research, Bioequivalency (BE) test research. Biological analysis services include the use of mass spectrometry analysis platform, immunoassay platform, cell analysis platform, molecular biology analysis platform for method development, method validation, biological sample detection research, etc. The firm mainly conducts its businesses in the domestic market.
See Also
What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
169m
CNY
Based on the financial report for Dec 31, 2024, Beijing Sun-Novo Pharmaceutical Research Co Ltd's Income from Continuing Operations amounts to 169m CNY.
What is Beijing Sun-Novo Pharmaceutical Research Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
29%
Over the last year, the Income from Continuing Operations growth was -8%. The average annual Income from Continuing Operations growth rates for Beijing Sun-Novo Pharmaceutical Research Co Ltd have been 16% over the past three years , 29% over the past five years .
